Roche: Q1 FY 2016 Results (Roche) - Apr 24, 2016 - Anticipated data from P1 trial of atezolizumab + RG7888 (anti-OX40 MAb) (NCT02410512) for solid tumors at ASCO (June 3-7, 2016); Anticipated data from P1 trial of atezolizumab + Cotellic (NCT01988896) for CRC at ASCO; Anticipated OS update from P2 POPLAR trial (NCT01903993) for 2/3L NSCLC at ASCO; Anticipated updates from first-line and second-line cohorts of P2 IMvigor210 trial (NCT02108652) for bladder cancer at ASCO; Anticipated update from P1 trial (NCT01633970) in combination with Abraxane in TNBC at ASCO
Anticipated P1 data • Anticipated P2 data • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Non Small Cell Lung Cancer • Oncology • Triple Negative Breast Cancer
|